Novel conditioning and prophylaxis regimens for relapse prevention

2.

Ruggeri

L

,

Capanni

M

,

Urbani

E

, et al.

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

.

Science

.

2002

;

295

(

5562

):

2097

-

2100

.

3.

Moretta

L

,

Ciccone

E

,

Poggi

A

,

Mingari

MC

,

Moretta

A.

Ontogeny, specific functions and receptors of human natural killer cells

.

Immunol Lett

.

1994

;

40

(

2

):

83

-

88

.

4.

Pende

D

,

Marcenaro

S

,

Falco

M

, et al.

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

.

Blood

.

2009

;

113

(

13

):

3119

-

3129

.

5.

Ruggeri

L

,

Mancusi

A

,

Capanni

M

, et al.

Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value

.

Blood

.

2007

;

110

(

1

):

433

-

440

.

6.

Davies

SM

,

Ruggieri

L

,

DeFor

T

, et al.

Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants

.

Blood

.

2002

Nov

15

;

100

(

10

):

3825

-

3827

.

7.

Giebel

S

,

Locatelli

F

,

Lamparelli

T

, et al.

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

.

Blood

.

2003

;

102

(

3

):

814

-

819

.

8.

Russo

A

,

Oliveira

G

,

Berglund

S

, et al.

NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications

.

Blood

.

2018

;

131

(

2

):

247

-

262

.

9.

Stern

M

,

Ruggeri

L

,

Mancusi

A

, et al.

Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor

.

Blood

.

2008

;

112

(

7

):

2990

-

2995

.

10.

Maloney

S

,

Smith

A

,

Furst

DE

, et al.

Microchimerism of maternal origin persists into adult life

.

J Clin Invest

.

1999

;

104

(

1

):

41

-

47

.

11.

Van Rood

JJ

,

Eernisse

JG

,

van Leeuwen

A.

Leucocyte antibodies in sera from pregnant women

.

Nature

.

1958

;

181

(

4625

):

1735

-

1736

.

12.

Ma

R

,

Huang

X-J

,

Xu

L-P

, et al.

Comparable outcomes after hematopoietic stem cell transplantation from mother donors and matched unrelated donors in patients with hematopoietic malignancies

.

Biol Blood Marrow Transplant

.

2019

;

25

(

6

):

1210

-

1217

.

13.

Ruggeri

L

,

Eikema

D-J

,

Bondanza

A

, et al.

Mother donors improve outcomes after HLA haploidentical transplantation: a study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

.

Transplant Cell Ther

.

2022

;

28

(

4

):

206.e1

-

206.e6

.

14.

Wang

Y

,

Chang

Y-J

,

Xu

L-P

, et al.

Who is the best donor for a related HLA haplotype-mismatched transplant?

Blood

.

2014

;

124

(

6

):

843

-

850

.

15.

Fleischhauer

K

,

Shaw

BE

,

Gooley

T

, et al;

International Histocompatibility Working Group in Hematopoietic Cell Transplantation

.

Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study

.

Lancet Oncol

.

2012

;

13

(

4

):

366

-

374

.

16.

Fleischhauer

K.

Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching

.

Hematology Am Soc Hematol Educ Program

.

2019

;

2019

(

1

):

532

-

538

.

17.

Cooley

S

,

Trachtenberg

E

,

Bergemann

TL

, et al.

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia

.

Blood

.

2009

;

113

(

3

):

726

-

732

.

18.

Schetelig

J

,

Baldauf

H

,

Heidenreich

F

, et al.

Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight

.

Front Immunol

.

2024

;

15

:

1350470

.

19.

Milano

F

,

Gooley

T

,

Wood

B

, et al.

Cord-blood transplantation in patients with minimal residual disease

.

N Engl J Med

.

2016

;

375

(

10

):

944

-

953

.

20.

Wagner

JE

,

Ballen

KK

,

Zhang

M-J

, et al.

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning

.

Blood Adv

.

2021

;

5

(

20

):

4064

-

4072

.

21.

Ruggeri

A

,

Galimard

J-E

,

Labopin

M

, et al.

Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myelogenous leukemia: a study on behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

.

Transplant Cell Ther

.

2022

;

28

(

10

):

710.e1

-

710710.e10

.

22.

Jethava

YS

,

Sica

S

,

Savani

B

, et al.

Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia

.

Bone Marrow Transplant

.

2017

;

52

(

11

):

1504

-

1511

.

23.

Scott

BL

,

Pasquini

MC

,

Logan

BR

, et al.

Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

.

J Clin Oncol

.

2017

;

35

(

11

):

1154

-

1161

.

24.

Scott

BL

,

Pasquini

MC

,

Fei

M

, et al.

Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes – long-term follow-up of the BMT CTN 0901 clinical trial

.

Transplant Cell Ther

.

2021

;

27

(

6

):

483.e1

-

483.e6

.

25.

Solomon

SR

,

St Martin

A

,

Shah

NN

, et al.

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy

.

Blood Adv

.

2019

;

3

(

19

):

2836

-

2844

.

26.

Devine

SM

,

Owzar

K

,

Blum

W

, et al.

Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from cancer and leukemia group B 100103 (Alliance for Clinical Trials in Oncology)/blood and marrow transplant clinical trial network 0502

.

J Clin Oncol

.

2015

;

33

(

35

):

4167

-

4175

.

27.

Hourigan

CS

,

Dillon

LW

,

Gui

G

, et al.

Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease

.

J Clin Oncol

.

2020

;

38

(

12

):

1273

-

1283

.

28.

Walter

RB

,

Gyurkocza

B

,

Storer

BE

, et al.

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

.

Leukemia

.

2015

;

29

(

1

):

137

-

144

.

29.

Festuccia

M

,

Deeg

HJ

,

Gooley

TA

, et al.

Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome

.

Biol Blood Marrow Transplant

.

2016

;

22

(

7

):

1227

-

1233

.

30.

Saraceni

F

,

Labopin

M

,

Hamladji

R-M

, et al;

Acute Leukemia Working Party of the European society for Blood and Marrow Transplantation (EBMT)

.

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission

.

Oncotarget

.

2018

;

9

(

3

):

3379

-

3393

.

31.

Sora

F

,

Grazia

CD

,

Chiusolo

P

, et al.

Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with busulfan and fludarabine (BUFLU) or thiotepa, busulfan, and fludarabine (TBF): a retrospective study

.

Biol Blood Marrow Transplant

.

2020

;

26

(

4

):

698

-

703

.

32.

Bazarbachi

A

,

Labopin

M

,

Blaise

D

, et al.

Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia

.

Bone Marrow Transplant

.

2021

;

56

(

3

):

622

-

634

.

33.

Kröger

N

,

Shimoni

A

,

Zabelina

T

, et al.

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)

.

Bone Marrow Transplant

.

2006

;

37

(

4

):

339

-

344

.

34.

Shimoni

A

,

Hardan

I

,

Shem-Tov

N

,

Rand

A

,

Yerushalmi

R

,

Nagler

A.

Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

.

Leuk Lymphoma

.

2007

;

48

(

12

):

2352

-

2359

.

35.

Casper

J

,

Holowiecki

J

,

Trenschel

R

, et al.

Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning

.

Bone Marrow Transplant

.

2012

;

47

(

9

):

1171

-

1177

.

36.

Ruutu

T

,

Volin

L

,

Beelen

DW

, et al.

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial

.

Haematologica

.

2011

;

96

(

9

):

1344

-

1350

.

37.

Nagler

A

,

Labopin

M

,

Beelen

D

, et al.

Long-term outcome after a treosulfan- based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

.

Cancer

.

2017

;

123

(

14

):

2671

-

2679

.

38.

Beelen

DW

,

Trenschel

R

,

Stelljes

M

, et al.

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

.

Lancet Haematol

.

2020

;

7

(

1

):

e28

-

e39

.

39.

Beelen

DW

,

Stelljes

M

,

Reményi

P

, et al.

Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial

.

Am J Hematol

.

2022

;

97

(

8

):

1023

-

1034

.

40.

Bredeson

C

,

LeRademacher

J

,

Kato

K

, et al.

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

.

Blood

.

2013

;

122

(

24

):

3871

-

3878

.

41.

Socié

G

,

Clift

RA

,

Blaise

D

, et al.

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

.

Blood

.

2001

;

98

(

13

):

3569

-

3574

.

42.

Nagler

A

,

Rocha

V

,

Labopin

M

, et al.

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) vs total-body irradiation plus Cy as conditioning regimen—a report from the acute leukemia working party of the European group for blood and marrow transplantation

.

J Clin Oncol

.

2013

;

31

(

28

):

3549

-

3556

.

43.

Litzow

MR

,

Pérez

WS

,

Klein

JP

, et al.

Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission

.

Br J Haematol

.

2002

;

119

(

4

):

1115

-

1124

.

44.

Clift

RA

,

Buckner

CD

,

Appelbaum

FR

, et al.

Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens

.

Blood

.

1990

;

76

(

9

):

1867

-

1871

.

45.

Clift

RA

,

Buckner

CD

,

Appelbaum

FR

,

Sullivan

KM

,

Storb

R

,

Thomas

ED

.

Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia

.

Blood

.

1998

;

92

(

4

):

1455

-

1456

.

46.

Peters

C

,

Dalle

J-H

,

Locatelli

F

, et al;

IBFM Study Group; IntReALL Study Group; I-BFM SCT Study Group; EBMT Paediatric Diseases Working Party

.

Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study

.

J Clin Oncol

.

2021

;

39

(

4

):

295

-

307

.

47.

Wong

JY

,

Liu

A

,

Schultheiss

T

, et al.

Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation

.

Biol Blood Marrow Transplant

.

2006

;

12

(

3

):

306

-

315

.

48.

Rosenthal

J

,

Wong

J

,

Stein

A

, et al.

Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies

.

Blood

.

2011

;

117

(

1

):

309

-

315

.

49.

Jensen

LG

,

Stiller

T

,

Wong

JYC

,

Palmer

J

,

Stein

A

,

Rosenthal

J.

Total marrow lymphoid irradiation/fludarabine/melphalan conditioning for allogeneic hematopoietic cell transplantation

.

Biol Blood Marrow Transplant

.

2018

;

24

(

2

):

301

-

307

.

50.

Stein

AS

,

Al Malki

MM

,

Yang

D

, et al.

Total marrow and lymphoid irradiation with posttransplantation cyclophosphamide for patients with AML in remission

.

Transplant Cell Ther

.

2022

;

28

(

7

):

368.e1

-

368.e7

.

51.

Al Malki

MM

,

Palmer

J

,

Tsai

N-C

, et al.

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

.

Blood Adv

.

2022

;

6

(

14

):

4098

-

4106

.

52.

Baron

F

,

Labopin

M

,

Peniket

A

, et al.

Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

.

Cancer

.

2015

;

121

(

7

):

1048

-

1055

.

53.

Elmariah

H

,

Otoukesh

S

,

Kumar

A

, et al.

Lower weight-based mycophenolate mofetil dosing is associated with superior outcomes after haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide

.

Transplant Cell Ther

.

2024

;

30

(

10

):

1019.e1

–

1019.e9

.

54.

Aversa

F

,

Tabilio

A

,

Velardi

A

, et al.

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

.

N Engl J Med

.

1998

;

339

(

17

):

1186

-

1193

.

55.

Aversa

F

,

Terenzi

A

,

Tabilio

A

, et al.

Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse

.

J Clin Oncol

.

2005

;

23

(

15

):

3447

-

3454

.

56.

Lang

P

,

Feuchtinger

T

,

Teltschik

H-M

, et al.

Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients

.

Bone Marrow Transplant

.

2015

;

50

(

suppl 2

):

S6

-

S10

.

57.

Locatelli

F

,

Merli

P

,

Pagliara

D

, et al.

Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion

.

Blood

.

2017

;

130

(

5

):

677

-

685

.

58.

Bertaina

A

,

Zecca

M

,

Buldini

B

, et al.

Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemia

.

Blood

.

2018

Dec

13

;

132

(

24

):

2594

-

2607

.

59.

Bleakley

M

,

Heimfeld

S

,

Loeb

KR

, et al.

Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts

.

J Clin Invest

.

2015

;

125

(

7

):

2677

-

2689

.

60.

Naik

S

,

Triplett

BM

.

Selective depletion of naïve T cells by targeting CD45RA

.

Front Oncol

.

2022

;

12

:

1009143

.

61.

Ciceri

F

,

Bonini

C

,

Stanghellini

MT

, et al.

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study

.

Lancet Oncol

.

2009

;

10

(

5

):

489

-

500

.

62.

Vago

L

,

Oliveira

G

,

Bondanza

A

, et al.

T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation

.

Blood

.

2012

;

120

(

9

):

1820

-

1830

.

63.

Zhou

X

,

Di Stasi

A

,

Tey

S-K

, et al.

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

.

Blood

.

2014

;

123

(

25

):

3895

-

3905

.

64.

Zhou

X

,

Dotti

G

,

Krance

RA

, et al.

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

.

Blood

.

2015

;

125

(

26

):

4103

-

4113

.

65.

Di Ianni

M

,

Falzetti

F

,

Carotti

A

, et al.

Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation

.

Blood

.

2011

;

117

(

14

):

3921

-

3928

.

66.

Brunstein

CG

,

Miller

JS

,

Cao

Q

, et al.

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics

.

Blood

.

2011

;

117

(

3

):

1061

-

1070

.

67.

Martelli

MF

,

Di Ianni

M

,

Ruggeri

L

, et al.

HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse

.

Blood

.

2014

;

124

(

4

):

638

-

644

.

68.

Pierini

A

,

Ruggeri

L

,

Carotti

A

, et al.

Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia

.

Blood Adv

.

2021

;

5

(

5

):

1199

-

1208

.

69.

Meyer

EH

,

Laport

G

,

Xie

BJ

, et al.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients

.

JCI Insight

.

2019

;

4

(

10

):

e127244

.

70.

Bader

CS

,

Pavlova

A

,

Lowsky

R

, et al.

Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD

.

Blood Adv

.

2024

;

8

(

5

):

1105

-

1115

.

71.

Armand

P

,

Kim

HT

,

Logan

BR

, et al.

Validation and refinement of the disease risk index for allogeneic stem cell transplantation

.

Blood

.

2014

;

123

(

23

):

3664

-

3671

.

72.

Toffalori

C

,

Zito

L

,

Gambacorta

V

, et al.

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

.

Nat Med

.

2019

;

25

(

4

):

603

-

611

.

73.

Ciurea

SO

,

Al Malki

MM

,

Kongtim

P

, et al.

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

.

Bone Marrow Transplant

.

2020

;

55

(

1

):

12

-

24

.

74.

Symons

HJ

,

Leffell

MS

,

Rossiter

ND

,

Zahurak

M

,

Jones

RJ

,

Fuchs

EJ

.

Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA- haploidentical bone marrow transplantation

.

Biol Blood Marrow Transplant

.

2010

;

16

(

4

):

533

-

542

.

75.

Brunstein

CG

,

Miller

JS

,

McKenna

DH

, et al.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect

.

Blood

.

2016

;

127

(

8

):

1044

-

1051

.